Sandy Primrose - Oxford BioDynamics Technical Consultant
| OXBOF Stock | USD 0.01 0.01 52.38% |
Insider
Sandy Primrose is Technical Consultant of Oxford BioDynamics Plc
| Phone | 44 1865 518 910 |
| Web | https://www.oxfordbiodynamics.com |
Oxford BioDynamics Management Efficiency
The company has return on total asset (ROA) of (0.4023) % which means that it has lost $0.4023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.446) %, meaning that it generated substantial loss on money invested by shareholders. Oxford BioDynamics' management efficiency ratios could be used to measure how well Oxford BioDynamics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | INSIDER Age | ||
| Barry MD | Immunitybio | 59 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Carol Waldo | Cidara Therapeutics | N/A | |
| Helen Luu | Immunitybio | N/A | |
| Sandeep MD | Immunitybio | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| Leonard MD | Immunitybio | N/A | |
| James Balkovec | Cidara Therapeutics | N/A | |
| Eyal MBA | Protalix Biotherapeutics | 48 | |
| Hans MD | Immunitybio | 74 | |
| David MBA | Seres Therapeutics | 63 | |
| David Sachs | Immunitybio | 46 | |
Management Performance
| Return On Equity | -1.45 | |||
| Return On Asset | -0.4 |
Oxford BioDynamics Plc Leadership Team
Elected by the shareholders, the Oxford BioDynamics' board of directors comprises two types of representatives: Oxford BioDynamics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oxford. The board's role is to monitor Oxford BioDynamics' management team and ensure that shareholders' interests are well served. Oxford BioDynamics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oxford BioDynamics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MA FCA, CFO Director | ||
| T Demain, Company Sec | ||
| Sandy Primrose, Technical Consultant | ||
| BSc BSC, CDO | ||
| Alexandre Ma, Chief Director | ||
| Thomas BA, Chief Officer | ||
| Jayne BSc, Director Operations | ||
| FACP MD, Group Director | ||
| Pr Gordon, Clinical Infection |
Oxford Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oxford BioDynamics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.45 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (55.85) % | |||
| Current Valuation | 37.52 M | |||
| Shares Outstanding | 146.71 M | |||
| Shares Owned By Insiders | 30.93 % | |||
| Shares Owned By Institutions | 52.67 % | |||
| Price To Book | 0.19 X | |||
| Price To Sales | 198.91 X | |||
| Revenue | 154 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Oxford Pink Sheet
Oxford BioDynamics financial ratios help investors to determine whether Oxford Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oxford with respect to the benefits of owning Oxford BioDynamics security.